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INTRODUCTION
Opportunistic protozoa are frequently path-
ogenic in HIV-infected patients. In these sub-
jects intestinal protozoa are a common cause of
severe enteritis and chronic diarrhea. The ill-
ness can be complicated by dehydratation and
malabsorption and can be life threatening.
Cryptosporidium parvum is among the
more common opportunist ic intest inal
pathogens in HIV-infected patients with an inci-
dence between 5% 1 and 38% 2. Intestinal
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Summary
In HIV-1 infected patients severe enteritis and chronic diarrhea are often
documented as a consequence of multiple opportunistic infections. We ana-
lyzed 48 HIV-1 positive patients for the presence of intestinal pathogenic pro-
tozoa. Patients with CD4 ≥200/mm3 showed a higher prevalence of a single
pathogenic protozoa than patients with CD4 ≤200/mm3, who showed the pres-
ence of multiple protozoal infections. Patients who proved positive for only a
single protozoa, Cryptosporidium or Blastocystis, were also positive, by stool
culture, for the presence of Proteus mirabilis (3 samples), Citrobacter fre-
undii (3 samples), Escherichia coli (one sample) or Enterobacter cloacae
(one sample). Treatment with rifaximin (600 mg, 3 times a day, for 14 days)
was efficacious in resolving the clinical symptoms and clearing protozoan infec-
tions in HIV-1 infected patients with CD4 ≥200/mm3, who presented enteric
and systemic symptoms due to Criptosporidium or Blastocystis associated
with enteropathogenic bacteria.
Key words: AIDS, chronic diarrhea, Cryptosporidium, Blastocystis, rifax-
imin.
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cryptosporidiosis is characterized by the pres-
ence of profuse and watery diarrhea, dehydra-
tion, rapid weight loss, and sometimes nausea,
vomiting, abdominal pain and fever. Once the
infection is established in patients with HIV
infection, the great majority of patients have
lifelong infection that is refractory to treatment.
Numerous drugs have been analyzed in humans
infected by Cryptosporidium, including paro-
momycin, spiramycin, azithromycin, clar-
ithromycin, octreotide, hyperimmune bovine
colostrum, bovine transfer factor and many oth-
ers. Because only limited numbers of trials have
been conducted with potential therapeutic
agents, the majority of information to date is
preliminary in nature 3.
Blastocystis hominis has for several
decades been considered a harmless yeast com-
mensal of the intestine but is nowadays classi-
fied as a pathogenic protozoa. In immunocom-
petent hosts B. hominis may be the cause of
an acute self limited diarrhea while in immuno-
compromised hosts it can cause prolonged or
recurrent diarrhea which can be associated with
abdominal pain, flatus, anorexia, fever and
sometimes eosinophilia. The success of treat-
ment with standard antiprotozoan agents has
been shown to be variable 4,5.
In HIV-infected patients diagnostic and ther-
apeutic approaches to enteric infections have
mainly been based on a single etiological agent
although some of these patients may harbor
multiple pathogens; moreover combination
antiretroviral therapy that includes a protease
inhibitor can restore immunity to C. parvum in
HIV-infected individuals and result in sustained
clinical and microbiological responses 6.
All these data prompted us to determine the
prevalence of C. parvum and B. hominis in
HIV-infected patients, treated with protease
inhibitors, and evaluate the possibility of coin-
fection with other bacterial agents. Moreover,
since rifaximin, an antimicrobial compound
derived from rifamycin SV 7, has been shown
to have an elective role in the treatment of
intestinal infections due to its broad antimicro-
bial spectrum, minimal intestinal absorption and
no significant side effects, in our study we
determined the efficacy of rifaximin on the
treatment of C. parvum and B. hominis intesti-
nal infections. The aim of this study was to
evaluate the efficacy and tolerability of rifaximin
in patients with stool cultures positive for proto-
zoan pathogens.
PATIENTS AND METHODS
Study population
From March 1996 to March 1998, 48 HIV-
seropositive patients, 26 females and 22 males,
with an average age of 28 years (range 12-54),
with enteric symptoms (mainly diarrhea) and/or
eosinophilia, were enrolled in the study.
HIV seropositivity was determined by the
presence of anti HIV-1 antibodies detected by
ELISA and immunoblotting. CD4+ lymphocyte
count was established by cytofluorimetric assay
and expressed as absolute number/mm3. At the
initial visit a standardized interview was admin-
istered and a physical examination performed.
All patients gave informed consent before eval-
uation.
Out of the 48 patients, 14 had CD4 values
<200/mm3 and all of them received antiretro-
viral therapy including at least one protease
inhibitor; in detail 8 patients received indinavir
(IDV) plus two reverse transcriptase inhibitors
(RTI), 5 patients received ritonavir (RTV) plus
two RTI and one patient received saquinavir
(SQV) plus two RTI. All these 14 patients had
received the therapy for no less than 14 days
and no longer than 3 months.
Out of the 48 enrolled patients, 34 showed
CD4 values >200/mm3 and 9 did not receive
any therapy while 25 received antiretroviral
therapy; in detail 10 patients received IDV plus
two RTI, 7 patients received RTV plus two RTI,
6 patients received SQV plus two RTI and 2
patients 2 RTI only. These 25 patients received
the therapy for no less than one month and no
longer than 15 months.
Fecal samples
Three fecal samples for each patient were
collected every other day and were transported
within 30 min to the laboratory. The samples
were processed for parasitological and bacterio-
logical analysis. Samples were examined micro-
scopically for ova, cysts and parasites with
iodine stain after concentration. The examina-
tion was complemented by the modified Ziehl-
Neelsen technique in search of C. parvum 8. In
brief, smears fixed in methanol for 3 min were
stained with carbolfuchsine for 5 min and then
decolorization in 3% hydrochloric acid in 93%
ethanol was performed. The smears were
rinsed in tap water and then counterstained in
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0.25% malachite green for 30 sec, rinsed again
and air dried.
To search for intestinal pathogenic bacteria,
stool specimens were inoculated into blood
agar and selective/differential agar plates for
intestinal bacteria.
Therapy
Patients positive for pathogens which were
identified by the techniques described above
were treated with rifaximin (NormixÆ tablets
200 mg), 600 mg three times per day for 14
days. During and after rifaximin therapy, each
patient was examined by the investigators who
obtained a detailed gastrointestinal history to
assess the patient’s response to therapy. A
daily diary of potential adverse reactions to the
drug was kept. The following parameters were
evaluated: bowel motions, stool characteristics,
abdominal pain, fever. Microbiological respons-
es were evaluated for clearing of the infectious
agents.
RESULTS
Out of the 48 HIV-infected patients studied
for parasitological examination, 15 (31%) were
positive for one or more protozoa and 33
(69%) proved negative, showing no potentially
infectious pathogens in the stools.
The results of the parasitological examina-
tion of the 15 positive patients along with the
patients’ CD4 values are shown in Table 1. In
all 6 patients with CD4 values >200/mm3 only
one pathogenic protozoa species was identified
for each patient. In the 9 patients with CD4
values <200/mm3, 5 patients had a single
pathogenic protozoa in their stools while 4
patients had two different pathogenic protozoa
concomitantly. Three subjects had C. parvum
only, one had Giardia intestinalis, one had
Isospora belli, while 3 out of the 4 patients
with multiple protozoan infections concomitant-
ly had C. parvum and Giardia and one C.
parvum and B. hominis.
The bacteriological stool culture in the 8
patients positive for C. parvum (6 patients) or
B. hominis (2 patients) as a single pathogenic
protozoa showed the copresence of different
pathogenic and non-pathogenic bacteria:
Proteus mirabilis (3 samples), Citrobacter fre-
undii (3 samples), Escherichia coli (one sam-
ple), Enterobacter cloacae (one sample). In
order to evaluate the efficacy of rifaximin in the
C. parvum and B. hominis infections with the
copresence of bacterial infections, the 3
patients with CD4 values >200/mm3 who were
positive both for C. parvum and enteropatho-
genic bacteria, and the 2 patients with CD4
values >200/mm3 positive both for B. hominis
and enteropathogenic bacteria were treated
with rifaximin.
The main clinical features evaluated during
the course of rifaximin therapy are summarized
in Table 2.
As regards bowel motions, al l treated
patients but one showed symptomatic improve-
ment on the fourth day. At the beginning of
the therapy, all 5 treated patients had loose or
watery stools which became formed after the
fourth day of therapy. Medium abdominal pain
was present at the beginning of therapy in 3
patients and after 4 days disappeared in 2 and
in one became mild. The 2 patients with fever
>37°C at the beginning of the therapy had a
temperature of ≤37°C on the second day of
therapy.
After 4 days of therapy all treated patients
experienced a complete remission of all symp-
toms (fever, abdominal pain and diarrhea).
After completing the course of rifaximin thera-
py, which occurred without any side effects, the
5 patients were examined for the presence of
stool parasites, three times at 2-day intervals.
All 5 patients proved negative in all the sam-
ples tested.
TABLE 1 - Intestinal protozoa in HIV patients.
C. parvum alone C. parvum + G. intestinalis C. parvum + B. hominis I. belli 
g. intestinalis B. hominis 
CD4 >200 (N. PTS.) 3 0 1 0 2 0 
CD4 <200 (N. PTS.) 3 3 1 1 0 1 
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DISCUSSION
Several opportunistic infections have been
documented in patients with HIV-1 infections,
of which those of the gastrointestinal tract are
prominent. This study documents the preva-
lence of intestinal protozoan infections in a
study group of 48 HIV infected subjects on
antiretroviral treatment with protease inhibitors
showing enteric and systemic symptoms. The
most frequently identified intestinal protozoa
was C. parvum, which was present either
alone or with other intestinal protozoa in 10
patients. The next most frequently identified
intestinal protozoa was G. intestinalis (5
patients) followed by B. hominis (3 patients)
and I. belli (one patient). Multiple protozoan
infections were noted in 4 patients who had
CD4 values <200/mm3. This demonstrates
that multiple opportunistic infections are more
frequent in subjects with a higher grade of
immunodeficiency.
C. parvum, either alone or with other
intestinal pathogens, was found in 10 cases
(20.8%) showing a decreased incidence with
respect to the values of 33% found in another
study, also performed in Italy in 1993 9. This
decreased value can be due to the fact that our
patients were treated with the new combination
antiretroviral therapy including protease
inhibitors which has been shown to restore
immunity to C. parvum 6. The decreased inci-
dence of pathogenic protozoa such as C.
parvum has been balanced by the increase in
low pathogenic opportunistic protozoa such as
B. hominis 10,11. In our study the presence of
Blastocystis, either alone or with other intesti-
nal protozoa, was documented in 6.2%
patients.
Since clinical intestinal manifestations in
HIV subjects can also be due to the concomi-
tant presence of protozoa and bacteria, in our
study we evaluated the presence of enteropath-
ogenic bacteria in the 8 patients who had C.
parvum or B. hominis as a single protozoan
agent and all proved positive for the presence
of bacteria. Among these 8 patients, 5 had
CD4 values >200/mm3 and thus were chosen
to be treated with rifaximin. We excluded the 3
subjects with CD4 values <200/mm3 from the
rifaximin treatment, since in these highly
immunocompromised patients specific antipro-
tozoan therapy has been shown to have limited
validity 12. All patients who were positive for B.
hominis and C. parvum and also showed the
presence of another microorganism, had a
complete resolution of symptoms after 4 days
of therapy when treated with rifaximin, with
clearance of C. parvum and B. hominis.
Therapy with oral rifaximin was well tolerated
in all patients and no specific complaints were
related to the therapy. Since the presence of
C. parvum and B. hominis had been accompa-
nied by positivity for enterobacteria in our rifax-
imin treated patients, we believe that by acting
as a regulator of intestinal bacterial population
rifaximin can alter the balance between infect-
ing intestinal protozoa and other coinfecting
intestinal bacteria.
TABLE 2 - Clinical monitoring of C. parvum and B. hominis patients.
N. bowel movements Stool characteristics Abdominal pain Fever (°C) 
Days on base- 1 2 3 4 base- 1 2 3 4 base- 1 2 3 4 base- 1 2 3 4
treatment line line line line 
C1* 3 3 2 1 1 L** L L F F ME§ ME ME A A 36.5 36.5 36.5 36.5 36.5
C2 3 3 2 2 2 W W W W F ME MI MI MI MI 37.5 37.5 36.5 36.5 36.5
C3 3 2 2 1 1 L L F F F ME ME ME ME A 38.5 38.5 37 36.5 36.5
B1 4 4 4 4 2 W W L L F A A A A A 36.5 36.5 36.5 36.5 36.5
B2 3 3 3 2 1 L L L F F A A A A A 36.5 36.5 36.5 36.5 36.5
*C=Pt With C. parvum **L=Loose §ME=Medium B=Pt With B. hominis F=Formed A=Absent W=Watery MI=Mild 
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